Table of Contents
PPT Slide
Safe Harbor Statement
Company Overview
Our Vision
Charles River Laboratories
Essential to the Process
Inveresk Merger
Inveresk Merger
Branding
Leading Capabilities Across the Drug Discovery and Development Pipeline
Uniquely Diverse Portfolio
Diversified Client Base
The New CRL – Reporting Segments
Global Footprint
Research Models and Services
Research Models and Services
Research Model Services
Pre-Clinical Services
Clinical Services
Clinical Services
Management Changes
Pre-Clinical Management Changes
Clinical Management Changes
Integration Update
Integration Update
2005 Synergies
2006 Synergies
Significant Market Opportunity
Forward Momentum
Reaffirming Q4 Guidance
Reaffirming 2004 Guidance
2004 Highlights
2005 Guidance
Future Direction
CRL: A Smart Investment
Financial Review
Net Sales
Sales Growth Drivers
Operating Margin
Margin Improvement Drivers
GAAP EPS
Non-GAAP EPS
EPS Improvement Drivers
Free Cash Flow
Cash Flow Improvements
New Debt Structure
Debt Structure
2004 4Q and Full-Year Guidance
2004 4Q Drivers
2005 Sales Guidance
2005 Amortization
2005 Guidance
2005 Cash Flow Guidance
SOX-404 Compliance
Summary
Pre-Clinical Services
Pre-Clinical Services
Management Structure
Pre-Clinical Locations
Creating Competitive Advantage
Pre-Clinical Vision
Integration
Sales and Marketing
Best Practices
Capacity Plans
Dedicated Capacity
Highly Complementary Service Offering
Leader in Specialty Toxicology
Unequaled Expertise in Repro Tox
Unequaled Expertise in Biologics
General Toxicology
Leadership in Pathology Services
Full-Service Preclinical Services
Strategic Growth Opportunities
Clinical Services
Clinical Services
Phase I
Phase I
European Clinical Trial Directive
Phase II-IV
Medical Data Services
Regulatory Affairs
Clinical Locations
Clinical Services Strategy
Core Market Growing at ~12.5%
Therapeutic Expertise
Therapeutic Area Focus
CRO Key Success Factors
Creating Competitive Advantage
Delivering Competitive Advantage
Delivering Competitive Advantage
Delivering Competitive Advantage
Growing Clinical Opportunity
Research Models and Services
RMS Overview
Research Models & Services (RMS)
Worldwide Market Opportunity
Research Models Worldwide Capacity
PPT Slide
Strategic Imperatives
Worldwide Strategies for Growth
Worldwide Strategies for Growth
Disease Models
Interrelated Disease Complications
Future Disease Models
Surgical Services
Capacity Additions
Hollister Expansion
Transgenic & Laboratory Services
Laboratory Services
Worldwide Strategies for Growth
In Vitro Detection Systems
FDA Mandated Assay
PTS Product Update
Vaccine Support Sales
Vaccine Support Strengths
Future Direction
|